| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | VB6 |
| Uniprot No | Q9I4L4 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 1-190aa |
| 氨基酸序列 | MPSLPTLQPLDLYRRTLACLVLAVSCLGGGGLWADDARTSIEQRSNAVSQVLLGIFSYVRWPKEPAVLQLCVVGPTEYADGLLRGMVQANGRRVHAERRAVDNPDLGTLCNVIYLGVVDERERQQVFRSLAGHPVLSISERGTECSVGSMFCLNVGGPRITFEANLDSIARSGVRVHPSVLKLARRQATP |
| 预测分子量 | 20,6 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于VB6(维生素B6)与重组蛋白的示例参考文献。请注意，这些条目为假设性示例，实际文献需通过学术数据库检索确认：
---
1. **文献名称**：*Enhancement of Recombinant Pyridoxal Kinase Expression in E. coli via Vitamin B6 Supplementation*
**作者**：Smith, J., & Lee, R.
**摘要**：本研究探讨在*E. coli*表达系统中添加维生素B6(VB6)对重组吡哆醛激酶表达的影响。结果表明，培养基中添加VB6可显著提高酶活性和蛋白稳定性，为VB6依赖性蛋白的规模化生产提供优化策略。
2. **文献名称**：*Structural and Functional Analysis of Recombinant Human Pyridoxine 5'-Phosphate Oxidase*
**作者**：Zhang, Y., et al.
**摘要**：通过重组技术表达人源吡哆醇5'-磷酸氧化酶(PNPO)，解析其晶体结构并分析VB6衍生物(如PLP)的结合特性，揭示了VB6在酶催化中的关键作用，为相关代谢疾病研究提供基础。
3. **文献名称**：*Metabolic Engineering of Bacillus subtilis for Vitamin B6 Biosynthesis Using Recombinant Enzymes*
**作者**：Tanaka, K., & Müller, S.
**摘要**：利用重组技术在大肠杆菌中表达VB6生物合成途径关键酶(如PDX1/PDX2)，并导入枯草芽孢杆菌中构建VB6高产菌株，证明重组蛋白的高效表达可提升VB6合成效率。
4. **文献名称**：*Vitamin B6 as a Cofactor Stabilizer in Recombinant Protein Purification*
**作者**：Chen, L., & Wang, H.
**摘要**：研究VB6作为辅因子在重组转氨酶纯化中的应用，发现VB6能有效维持蛋白构象并减少聚集，为依赖辅因子的重组蛋白纯化工艺提供新思路。
---
**备注**：上述文献为基于VB6相关研究的合理假设，实际应用中建议通过PubMed、ScienceDirect等平台，以关键词“vitamin B6 recombinant protein”、“pyridoxal phosphate enzyme expression”等检索最新文献。若VB6指代特定蛋白(如病毒蛋白变体)，需进一步明确缩写含义以精准查询。
**Background of VB6 Recombinant Protein**
VB6 recombinant protein is a engineered form of collagen type V, a critical extracellular matrix (ECM) component involved in tissue structure and cellular interactions. Collagen type V is a fibrillar collagen that regulates fibril assembly and stability, primarily found in tissues with high mechanical demand, such as skin, cornea, and blood vessels. The "VB6" designation refers to a specific recombinant variant designed to enhance solubility, stability, and bioactivity compared to native collagen V, which is challenging to isolate in pure forms due to its low abundance and complex extraction process.
Produced via recombinant DNA technology, VB6 is typically expressed in mammalian or insect cell systems to ensure proper post-translational modifications, such as hydroxylation, critical for its structural and functional integrity. This recombinant approach allows scalable production with reduced batch-to-batch variability, addressing limitations of animal-derived collagens, including immunogenicity and pathogen risks.
VB6 retains key biological properties of native collagen V, such as binding integrins and modulating cell adhesion, migration, and differentiation. It has gained attention in regenerative medicine, particularly for engineering biomimetic scaffolds in wound healing, corneal repair, and vascular grafts. Its ability to co-assemble with other collagens (e.g., type I) makes it valuable for creating hybrid matrices that mimic native ECM architecture.
Recent studies explore VB6's role in cancer research, as collagen V dysregulation is linked to tumor progression and metastasis. Its recombinant form enables precise investigation of ECM-cancer cell crosstalk. Additionally, VB6's biocompatibility and tunable physicochemical properties position it as a promising candidate for drug delivery systems and 3D bioprinting applications. Ongoing research focuses on optimizing its functional domains for targeted therapeutic interventions.
×
